Australia - English - Department of Health (Therapeutic Goods Administration)

cisatracurium besylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira pty limited - cisatracurium besylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - mivacurium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cisatracurium besylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.669 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - botulinum toxin type a 50 u - powder for injection - 50 u - active: botulinum toxin type a 50 u excipient: albumin sodium chloride - · for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month with headache lasting 4 hours a day or longer, of which at least 8 days are with migraine)

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - botulinum toxin type a 100 u - powder for injection - 100 u - active: botulinum toxin type a 100 u excipient: albumin sodium chloride - botox® (botulinum toxin type a) purified neurotoxin complex is indicated: · for the prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month with headache lasting 4 hours a day or longer, of which at least 8 days are with migraine)